A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Breast Cancer
- Colorectal Cancer
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Non -Small Cell Lung Cancer
- Other Solid Tumors
- Pancreatic Ductal Carcinoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: Proposed dose Cohorts Cohort A?1mg Cohort B?2mg Cohort C?4mg Cohort D: 6mg Cohort E?8mgMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04121286
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Yuankai Shi, MD Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Get Well Soon